Medical treatment of gastrinomas

Wiener Klinische Wochenschrift

Volumn 119, Issue 19-20, 2007, Pages 609-615

  Auernhammer, Christoph J ^a   Göke, Burkhard ^a,b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

Chemotherapy; Gastrinoma; Interferon; Proton pump inhibitors; Somatostatin analogues

Indexed keywords

ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; ANGIOPEPTIN; ANTINEOPLASTIC AGENT; BETA INTERFERON; BEVACIZUMAB; CISPLATIN; DOXORUBICIN; ESOMEPRAZOLE; ETOPOSIDE; EVEROLIMUS; FLUOROURACIL; GEFITINIB; IMATINIB; LANSOPRAZOLE; OCTREOTIDE; OMEPRAZOLE; PANTOPRAZOLE; PEGINTERFERON; PHOSPHOTRANSFERASE INHIBITOR; PROTON PUMP INHIBITOR; RABEPRAZOLE; SOMATOSTATIN DERIVATIVE; SOMATULINE AUTOGEL; SORAFENIB; STREPTOZOCIN; SUNITINIB; TEMSIROLIMUS; UNCLASSIFIED DRUG;

ABDOMINAL DISCOMFORT; BRAIN CANCER; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER SIZE; CARDIOTOXICITY; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG BINDING; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; FLATULENCE; GALLSTONE FORMATION; GASTRINOMA; HUMAN; META ANALYSIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NEUROENDOCRINE TUMOR; PROSPECTIVE STUDY; PROTEINURIA; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; STOMACH ACID; STOMACH SURGERY; SYSTEMATIC REVIEW; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; ZOLLINGER ELLISON SYNDROME;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; DUODENAL NEOPLASMS; GASTRINOMA; GASTRINS; HUMANS; INTERFERON-ALPHA; OCTREOTIDE; PANCREATIC NEOPLASMS; PEPTIDES, CYCLIC; PROTON PUMP INHIBITORS; SOMATOSTATIN; ZOLLINGER-ELLISON SYNDROME;

EID: 35848952066     PISSN: 00435325     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00508-007-0877-1     Document Type: Review

References (76)

1. Brandi ML, Gagel RF, Angeli A, Bilezikian JP, Beck-Peccoz P, Bordi C, et al (2001) Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 86: 5658-5671
2. Jensen RT (2004) Gastrinomas: advances in diagnosis and management. Neuroendocrinology 80 [Suppl 1]: 23-27
3. Oberg K, Astrup L, Eriksson B, Falkmer SE, Falkmer UG, Gustafsen J, et al (2004) Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms). Part II-specific NE tumour types. Acta Oncol 43: 626-636
4. DeLellis RA, Lloyd RV, Heitz PU, Eng C (2004) World Health Organization classification of tumours. Pathology & genetics. Tumours of endocrine organs. IARC Press, Lyon
5. Hoffmann KM, Furukawa M, Jensen RT (2005) Duodenal neuroendocrine tumors: classification, functional syndromes, diagnosis and medical treatment. Best Pract Res Clin Gastroenterol 19: 675-697
6. Plockinger U, Rindi G, Arnold R, Eriksson B, Krenning EP, de Herder WW, et al (2004) Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS). Neuroendocrinology 80: 394-424
7. Ramage JK, Davies AH, Ardill J, Bax N, Caplin M, Grossman A, et al (2005) Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. Gut 54 [Suppl 4]: iv1-16
8. Jensen RT, Niederle B, Mitry E, Ramage JK, Steinmüller T, Lewington V, et al (2006) ENETS Guidelines. Gastrinoma (Duodenal and Pancreatic) Neuroendocrinology 84: 173-182
9. Goudet P, Peschaud F, Mignon M, Nicoli-Sire P, Cadiot G, Ruszniewski P, et al (2004) Gastrinomas in multiple endocrine neoplasia type-1. A 127-case cohort study from the endocrine tumor group (ETG). Ann Chir 129: 149-155
10. Yu F, Venzon DJ, Serrano J, Goebel SU, Doppman JL, Gibril F, et al (1999) Prospective study of the clinical course, prognostic factors, causes of death, and survival in patients with long-standing Zollinger-Ellison syndrome. J Clin Oncol 17: 615-630
11. Warner RR (2005) Enteroendocrine tumors other than carcinoid: a review of clinically significant advances. Gastroenterology 128: 1668-1688
12. Kaltsas GA, Besser GM, Grossman AB (2004) The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev 25: 458-511
13. Modlin IM, Kidd M, Latich I, Zikusoka MN, Shapiro MD (2005) Current status of gastrointestinal carcinoids. Gastroenterology 128: 1717-1751
14. Oberg K, Astrup L, Eriksson B, Falkmer SE, Falkmer UG, Gustafsen J, et al (2004) Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms). Part I - general overview. Acta Oncol 43: 617-625
15. Pisegna JR, Norton JA, Slimak GG, Metz DC, Maton PN, Gardner JD, et al (1992) Effects of curative gastrinoma resection on gastric secretory function and antisecretory drug requirement in the Zollinger-Ellison syndrome. Gastroenterology 102: 767-777
16. Calvet X, Gomollon F (2005) What is potent acid inhibition, and how can it be achieved? Drugs 65 [Suppl 1]: 13-23
17. Frucht H, Maton PN, Jensen RT (1991) Use of omeprazole in patients with Zollinger-Ellison syndrome. Dig Dis Sci 36: 394-404
18. Desir B, Poitras P (2001) Oral pantoprazole for acid suppression in the treatment of patients with Zollinger-Ellison syndrome. Can J Gastroenterol 15: 795-798
19. Hirschowitz BI, Mohnen J, Shaw S (1996) Long-term treatment with lansoprazole for patients with Zollinger-Ellison syndrome. Aliment Pharmacol Ther 10: 507-522
20. Metz DC, Pisegna JR, Ringham GL, Feigenbaum K, Koviack PD, Maton PN, et al (1993) Prospective study of efficacy and safety of lansoprazole in Zollinger-Ellison syndrome. Dig Dis Sci 38: 245-256
21. Carswell CI, Goa KL (2001) Rabeprazole: an update of its use in acid-related disorders. Drugs 61: 2327-2356
22. Mearin F, Ponce J (2005) Potent acid inhibition: summary of the evidence and clinical application. Drugs 65 [Suppl 1]: 113-126
23. Termanini B, Gibril F, Sutliff VE, Yu F, Venzon DJ, Jensen RT (1998) Effect of long-term gastric acid suppressive therapy on serum vitamin B12 levels in patients with Zollinger-Ellison syndrome. Am J Med 104: 422-430
24. Oberg K, Kvols L, Caplin M, Delle Fave G, de Herder W, Rindi G, et al (2004) Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol 15: 966-973
25. Kulaksiz H, Eissele R, Rossler D, Schulz S, Hollt V, Cetin Y, et al (2002) Identification of somatostatin receptor subtypes 1, 2A, 3, and 5 in neuroendocrine tumours with subtype specific antibodies. Gut 50: 52-60
26. Bonfils S, Ruszniewski P, Costil V, Laucournet H, Vatier J, Rene E, et al (1986) Prolonged treatment of Zollinger-Ellison syndrome by long-acting somatostatin. Lancet 1(8480): 554-555
27. Vinik AI, Tsai S, Moattari AR, Cheung P (1988) Somatostatin analogue (SMS 201-995) in patients with gastrinomas. Surgery 104: 834-842
28. Ruszniewski P, Laucournet H, Elouaer-Blanc L, Mignon M, Bonfils S (1988) Long-acting somatostatin (SMS 201-995) in the management of Zollinger-Ellison syndrome: evidence for sustained efficacy. Pancreas 3: 145-152
29. Bauer FE, Hummel M, Merki HS, Schulz E, Oeder R, Marbach P (1989) Long-acting somatostatin analog controls acid and gastrin secretion in benign, not in malignant, Zollinger-Ellison syndrome. J Clin Gastroenterol 11: 282-286
30. Vinik AI, Lloyd R, Cho K (1990) The use of somatostatin analog in gastroenteropancreatic tumors other than carcinoid. Metabolism 9 [Suppl 2]: 156-162
31. Mozell EJ, Cramer AJ, O'Dorisio TM, Woltering EA (1992) Long-term efficacy of octreotide in the treatment of Zollinger-Ellison syndrome. Arch Surg 127: 1019-1024
32. Hofland LJ, van Koetsveld PM, Waaijers M, Zuyderwijk J, Lamberts SW (1994) Relative potencies of the somatostatin analogs octreotide, BIM-23014, and RC-160 on the inhibition of hormone release by cultured human endocrine tumor cells and normal rat anterior pituitary cells. Endocrinology 134: 301-306
33. Gaztambide S, Vazquez JA (1999) Short- and long-term effect of a long-acting somatostatin analogue, lanreotide (SR-L) on metastatic gastrinoma. J Endocrinol Invest 22: 144-146
34. Burgess JR, Greenaway TM, Parameswaran V, Shepherd JJ (1999) Octreotide improves biochemical, radiologic, and symptomatic indices of gastroenteropancreatic neoplasia in patients with multiple endocrine neoplasia type 1 (MEN-1). Implications for an integrated model of MEN-1 tumorigenesis. Cancer 86: 2154-2159
35. Peghini PL, Annibale B, Azzoni C, Milione M, Corleto VD, Gibril F, et al (2002) Effect of chronic hypergastrinemia on human enterochromaffin-like cells: insights from patients with sporadic gastrinomas. Gastroenterology 123: 68-85
36. Shojamanesh H, Gibril F, Louie A, Ojeaburu JV, Bashir S, Abou-Saif A, et al (2002) Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma. Cancer 94: 331-343
37. Arnold R, Rinke A, Klose KJ, Muller HH, Wied M, Zamzow K, et al (2005) Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial. Clin Gastroenterol Hepatol 3: 761-771
38. Faiss S, Pape UF, Bohmig M, Dorffel Y, Mansmann U, Golder W, et al (2003) Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors - the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol 21: 2689-2696
39. Wymenga AN, Eriksson B, Salmela PI, Jacobsen MB, Van Cutsem EJ, Fiasse RH, et al (1999) Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms. J Clin Oncol 17: 1111-1117
40. Ricci S, Antonuzzo A, Galli L, Orlandini C, Ferdeghini M, Boni G, et al (2000) Long-acting depot lanreotide in the treatment of patients with advanced neuroendocrine tumors. Am J Clin Oncol 23: 412-415
41. Pisegna JR, Slimak GG, Doppman JL, Strader DB, Metz DC, Benya RV, et al (1993) An evaluation of human recombinant alpha interferon in patients with metastatic gastrinoma. Gastroenterology 105: 1179-1183
42. Eriksson B, Oberg K, Alm G, Karlsson A, Lundqvist G, Andersson T, et al (1986) Treatment of malignant endocrine pancreatic tumours with human leucocyte interferon. Lancet 2 (8519): 1307-1309
43. Frank M, Klose KJ, Wied M, Ishaque N, Schade-Brittinger C, Arnold R (1999) Combination therapy with octreotide and alpha-interferon: effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors. Am J Gastroenterol 94: 1381-1387
44. Rougier P, Mitry E (2000) Chemotherapy in the treatment of neuroendocrine malignant tumors. Digestion 62 [Suppl 1]: 73-78
45. O'Toole D, Hentic O, Corcos O, Ruszniewski P (2004) Chemotherapy for gastro-enteropancreatic endocrine tumours. Neuroendocrinology 80 [Suppl 1]: 79-84
46. Rindi G, Klöppel G, Alhman H, Caplin M, Couvelard A, de Herder WW, et al (2006) TNM staging of foregut (neuro)endocrine tumors: a consesnsus propsal including a grading system. Virchows Arch 449: 395-401
47. von Schrenck T, Howard JM, Doppman JL, Norton JA, Maton PN, Smith FP, et al (1988) Prospective study of chemotherapy in patients with metastatic gastrinoma. Gastroenterology 94: 1326-1334
48. Ruszniewski P, Hochlaf S, Rougier P, Mignon M (1991) Intravenous chemotherapy with streptozotocin and 5 fluorouracil for hepatic metastases of Zollinger-Ellison syndrome. A prospective multicenter study in 21 patients. Gastroenterol Clin Biol 15: 393-398
49. Arnold R, Rinke A, Schmidt Ch, Hofbauer L (2005) Chemotherapy. Best Pract Res Clin Gastroenterol 19: 649-656
50. Nilsson O, Cutsem EV, Fave GD, Yao JC, Pavel ME, McNicol AM et al (2006) Poorly differentiated carcinomas of the foregut (gastric, duodenal and pancreatic). Neuroendocrinology 84: 212-215
51. Moertel CG, Kvols LK, O'Connell MJ, Rubin J (1991) Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 68: 227-232
52. Mitry E, Baudin E, Ducreux M, Sabourin JC, Rufie P, Aparicio T, et al (1999) Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer 81: 1351-1355
53. Fjallskog ML, Granberg DP, Welin SL, Eriksson C, Oberg KE, Janson ET, et al (2001) Treatment with cisplatin and etoposide in patients with neuroendocrine tumors. Cancer 92: 1101-1107
54. Vitale G, de Herder WW, van Koetsveld PM, Waaijers M, Schoordijk W, Croze E, et al (2006) IFN-(beta) is a highly potent inhibitor of gastroenteropancreatic neuroendocrine tumor cell growth in vitro. Cancer Res 66: 554-562
55. Zitzmann K, Brand S, De Toni EN, Baehs S, Göke B, Meinecke J, et al (2007) SOCS1 silencing enhances antitumor activity of type I IFNs by regulating apoptosis in neuroendocrine tumor cells. Cancer Res 67 (in press)
56. Zikusoka MN, Kidd M, Eick G, Latich I, Modlin IM (2005) The molecular genetics of gastroenteropancreatic neuroendocrine tumors. Cancer 104: 2292-2309
57. Wiedenmann B, Pape UF (2004) From basic to clinical research in gastroenteropancreatic neuroendocrine tumor disease - the clinician-scientist perspective. Neuroendocrinology 80 [Suppl 1]: 94-99
58. Grotzinger C (2004) Tumour biology of gastroenteropancreatic neuroendocrine tumours. Neuroendocrinology 80 [Suppl 1]: 8-11
59. Duran I, Salazar R, Casanovas O, Arrazubi V, Vilar E, Siu LL, et al (2007) New drug development in digestive neuroendocrine tumors. Ann Oncol 18: 1307-1313
60. Strosberg JR, Kvols LK (2007) A review of the current clinical trials for gastroenteropancreatic neuroendocrine tumours. Expert Opin Investig Drugs 16: 219-224
61. Turner HE, Harris AL, Melmed S, Wass JA (2003) Angiogenesis in endocrine tumors. Endocr Rev 24: 600-632
62. Pavel ME, Hassler G, Baum U, Hahn EG, Lohmann T, Schuppan D (2005) Circulating levels of angiogenic cytokines can predict tumour progression and prognosis in neuroendocrine carcinomas. Clin Endocrinol (Oxf) 62: 434-443
63. Zhang J, Jia Z, Li Q, Wang L, Rashid A, Zhu Z, et al (2007) Elevated expression of vascular endothelial growth factor correlates with increased angiogenesis and decreased progression-free survival among patients with low-grade neuroendocrine tumors. Cancer 109: 1478-1486
64. Lankat-Buttgereit B, Horsch D, Barth P, Arnold R, Blocker S, Goke R (2005) Effects of the tyrosine kinase inhibitor imatinib on neuroendocrine tumor cell growth. Digestion 71: 131-140
65. Ferrari L, Della Torre S, Collini P, Martinetti A, Procopio G, De Dosso S, et al (2006) Kit protein (CD117) and proliferation index (Ki-67) evaluation in well and poorly differentiated neuroendocrine tumors. Tumori 92: 531-535
66. Welin S, Fjallskog ML, Saras J, Eriksson B, Janson ET (2006) Expression of tyrosine kinase receptors in malignant midgut carcinoid tumors. Neuroendocrinology 84: 42-48
67. Yao JC, Zhang JX, Rashid A, Yeung SC, Szklaruk J, Hess K, et al (2007) Clinical and in vitro studies of imatinib in advanced carcinoid tumors. Clin Cancer Res. 13: 234-240
68. Papouchado B, Erickson LA, Rohlinger AL, Hobday TJ, Erlichman C, Ames MM, et al (2005) Epidermal growth factor receptor and activated epidermal growth factor receptor expression in gastrointestinal carcinoids and pancreatic endocrine carcinomas. Mod Pathol 18: 1329-1335
69. Shah T, Hochhauser D, Frow R, Quaglia A, Dhillon AP, Caplin ME (2006) Epidermal growth factor receptor expression and activation in neuroendocrine tumours. J Neuroendocrinol 18: 355-360
70. Gilbert JA, Lloyd RV, Ames MM (2005) Lack of mutations in EGFR in gastroenteropancreatic neuroendocrine tumors. N Engl J Med 353: 209-210
71. Hopfner M, Sutter AP, Gerst B, Zeitz M, Scherubl H (2003) A novel approach in the treatment of neuroendocrine gastrointestinal tumours. Targeting the epidermal growth factor receptor by gefitinib (ZD1839). Br J Cancer 89: 1766-1775
72. Furukawa M, Raffeld M, Mateo C, Sakamoto A, Moody TW, Ito T, et al (2005) Increased expression of insulinlike growth factor I and/or its receptor in gastrinomas is associated with low curability, increased growth, and development of metastases. Clin Cancer Res 11: 3233-3242
73. von Wichert G, Jehle PM, Hoeflich A, Koschnick S, Dralle H, Wolf E, Wiedenmann B, Boehm BO, Adler G, Seufferlein T (2000) Insulin-like growth factor-I is an autocrine regulator of chromogranin A secretion and growth in human neuroendocrine tumor cells. Cancer Res 60: 4573-4581
74. Zitzmann K, De Toni EN, Brand S, Goke B, Meinecke J, Spottl G, et al (2007) The novel mTOR inhibitor RAD001 (Everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells. Neuroendocrinology 85: 54-60
75. Duran I, Kortmansky J, Singh D, Hirte H, Kocha W, Goss G, et al (2006) A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br J Cancer 95(9): 1148-54
76. Karhoff D, Sauer S, Schrader J, Arnold R, Fendrich V, Bartsch DK, et al (2007) Rap1/B-raf signaling is activated in neuroendocrine tumors of the digestive tract and raf kinase inhibition constitutes a putative therapeutic target. Neuroendocrinology 85: 45-53